AstraZeneca's Breast Cancer Drug Camizestrant Fails to Meet Primary Endpoint in Late-Stage Trial

AstraZeneca announced that its breast cancer pill camizestrant (Etcamah), when tested in combination with Pfizer's Ibrance, did not meet the primary goal of improving progression-free survival in a late-stage trial for previously untreated patients with a form of advanced breast cancer. This development follows the drug's recent U.S. approval for a different indication (ESR1 mutation).